Answers are grounded in this paper and cite their sources.
Within the European Union (EU), and by contrast with other countries (notably the USA), only a limited number of insurance companies reimburse treatment with repetitive transcranial magnetic stimulation (rTMS) and none with transcranial electrical stimulation (tES). As a consequence, there is significant risk that treatment availability and investment in research and clinical developments in non-invasive brain stimulation (NIBS) in Europe will fall behind. Unexpectedly, a sudden unwelcome regulatory change has made the European situation even worse.
No takes yet. Share an insight, caveat, or question.
Baeken et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: